Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
CALGB 100104 trial: what clinicians have said so far
Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant
- NCT00114101 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Deep size, estimated: 301+ verified statements once built
We haven't built an HCP commentary report on CALGB 100104 (lenalidomide in multiple myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CALGB 100104 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 29 posts on X, typically up to 128 once built | |
| 1 YouTube video, typically up to 4 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase III Randomized, Double-Blind Study of Maintenance Therapy With CC-5013 (NSC # 703813) or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- DS Stage I Multiple Myeloma; DS Stage II Multiple Myeloma; DS Stage III Multiple Myeloma; Refractory Multiple Myeloma; Smoldering Multiple Myeloma
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation; Laboratory Biomarker Analysis; Lenalidomide; Melphalan; Peripheral Blood Stem Cell Transplantation; Placebo Administration
- Arms
- Arm I (melphalan, autologous PBSCT, lenalidomide) · Experimental
- Arm II (melphalan, autologous PBSCT, placebo) · Placebo comparator
- Enrollment
- 460
- Primary outcomes
- Time to Progression
- Sponsor
- National Cancer Institute (NCI)
- Start
- Dec 15, 2004
- Primary completion
- Dec 31, 2012
- Results posted
- Yes
- Registry record
- NCT00114101 · updated Nov 13, 2026
Publications
linked from the registry- Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep;4(9):e431-e442. doi: 10.1016/S2352-3026(17)30140-0. Epub 2017 Aug 17. PubMed 28826616
- McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10;366(19):1770-81. doi: 10.1056/NEJMoa1114083. PubMed 22571201